Cannabis for Gynecological Pain: Growing Patient Use, Limited Clinical Evidence
Women are increasingly using cannabis for endometriosis, pelvic pain, and period cramps — with retrospective data suggesting benefit — but clinical trials are nearly nonexistent.
Quick Facts
What This Study Found
Cannabis has a long history of use for menstrual and reproductive pain, predating modern medicine by centuries. This review examines the current evidence for cannabis in gynecological pain conditions — endometriosis, chronic pelvic pain, and primary dysmenorrhea (period cramps) — and finds a familiar pattern: lots of patient use, some encouraging retrospective data, but almost no controlled clinical evidence.
The growing evidence base comes primarily from retrospective studies, cohort data, and patient surveys. These consistently show that women are using cannabis for gynecological pain, that many find it helpful, and that it may reduce reliance on other pain medications. The most evidence exists for endometriosis, where surveys of patients report significant symptom relief, particularly for pain, sleep, and mood.
But the obstacles to medical cannabis adoption for these conditions go beyond the evidence gap. The authors identify a constellation of barriers: outdated drug-driving laws that penalize patients even when not impaired, workplace drug testing policies, the cost of quality-assured medical cannabis (not covered by insurance), a lack of cannabis education among healthcare professionals, and persistent stigma — particularly for women using cannabis.
The review notes that most women currently using cannabis for gynecological pain are using illicit rather than medical cannabis, largely because of these access barriers. This means they're using uncontrolled products without clinical guidance, which is suboptimal for both efficacy and safety.
Key Numbers
Endometriosis affects approximately 10% of reproductive-age women. Most cannabis use for gynecological pain is with illicit rather than medical cannabis. The review identifies five key barriers to medical cannabis adoption: drug-driving laws, workplace testing, cost, clinician education gaps, and stigma. Clinical trial data for cannabis in any gynecological pain condition is described as lacking.
How They Did This
Retrospective cohort analysis and narrative review of evidence for cannabis use in gynecological pain conditions (endometriosis, chronic pelvic pain, primary dysmenorrhea). Examined published retrospective data, surveys, and cohort studies, as well as barriers to medical cannabis adoption.
Why This Research Matters
Gynecological pain affects millions of women and is chronically undertreated. Endometriosis alone affects 10% of reproductive-age women, with limited effective treatments and an average 7-10 year diagnostic delay. Many patients have already turned to cannabis out of desperation — this review maps what we know and don't know about whether that's a good idea, and identifies the systemic barriers preventing better evidence from being gathered.
The Bigger Picture
This sits alongside RTHC-00099 (chronic pain patient experiences) in documenting the gap between patient use of cannabis and clinical evidence supporting it. The barrier analysis — stigma, cost, testing, clinician ignorance — echoes the workplace policy challenges described in RTHC-00082. For women with gynecological pain, these barriers compound: cannabis stigma layers on top of the existing stigma around women's pain being dismissed or undertreated.
What This Study Doesn't Tell Us
Most evidence comes from retrospective and survey data, which cannot establish causation. Self-reported cannabis effectiveness may reflect placebo effects, expectation bias, or recall bias. The review doesn't present original data. Clinical trial evidence is acknowledged as essentially absent. The review focuses on cannabis generally rather than specific cannabinoids, doses, or routes of administration. Geographic and legal variation in cannabis access limits the generalizability of findings.
Questions This Raises
- ?Would a randomized trial of medical cannabis for endometriosis pain show superiority over placebo?
- ?Which cannabinoid profiles and routes of administration are most effective for gynecological pain?
- ?Could cannabis reduce the need for hormonal treatments or opioids in endometriosis patients?
- ?How can clinician education about cannabis be improved to better serve women with these conditions?
Trust & Context
- Key Stat:
- Evidence Grade:
- This is a review combining retrospective cohort data with narrative synthesis. The patient use data is consistent but comes from uncontrolled settings. No randomized clinical trials exist for cannabis in gynecological pain.
- Study Age:
- Published in 2023. Clinical trials for cannabis in endometriosis and other gynecological conditions may be underway.
- Original Title:
- The Place of Cannabinoids in the Treatment of Gynecological Pain.
- Published In:
- Drugs, 83(17), 1571-1579 (2023) — Drugs is a well-respected journal that publishes comprehensive reviews and studies on pharmacology and therapeutics.
- Authors:
- Sinclair, Justin(14), Abbott, Jason(6), Proudfoot, Andrew(2), Armour, Mike
- Database ID:
- RTHC-04945
Evidence Hierarchy
Looks back at existing records to find patterns.
What do these levels mean? →Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- why-does-weed-make-you-sleepy-thc-sleep
- why-weed-energetic-or-sleepy-difference
- why-weed-makes-me-anxious-now-not-before
- thc-and-melatonin-combine-sleep
- cannabis-and-fibromyalgia-evidence-dosing
- cannabis-and-carpal-tunnel-nerve-pain
- cannabis-and-migraines-prevention-treatment
- cannabis-and-endometriosis-thc-pain
- cannabis-and-parkinsons-disease-tremor-sleep
- using-weed-to-sleep-every-night-long-term
- sleep-hygiene-cannabis-users
- cannabis-sleep-architecture-deep-rem
- cbd-for-sleep-does-it-work
- weed-and-sleep-apnea
- cannabis-vs-sleep-aids-comparison
- edibles-for-sleep-dosing-timing
Cite This Study
https://rethinkthc.com/research/RTHC-04945APA
Sinclair, Justin; Abbott, Jason; Proudfoot, Andrew; Armour, Mike. (2023). The Place of Cannabinoids in the Treatment of Gynecological Pain.. Drugs, 83(17), 1571-1579. https://doi.org/10.1007/s40265-023-01951-z
MLA
Sinclair, Justin, et al. "The Place of Cannabinoids in the Treatment of Gynecological Pain.." Drugs, 2023. https://doi.org/10.1007/s40265-023-01951-z
RethinkTHC
RethinkTHC Research Database. "The Place of Cannabinoids in the Treatment of Gynecological ..." RTHC-04945. Retrieved from https://rethinkthc.com/research/sinclair-2023-the-place-of-cannabinoids
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.